Lee Jin Hyeog, Seo Jun Hye, Koo Tai Yeon, Cho Jang Hee, Kang Kyung Pyo, Lee Jung Eun, Oh Kook Hwan, Kim Beom Seok, Yang Jaeseok
Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Division of Nephrology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
Kidney Res Clin Pract. 2025 Sep;44(5):834-847. doi: 10.23876/j.krcp.24.033. Epub 2024 Jun 4.
Patients with sensitization and blood type O experience increased waiting times for deceased-donor kidney transplantation (DDKT). While allocation benefits are needed to resolve inequity in DDKT opportunity, whether DDKT has comparable outcomes in this disadvantaged population requires further study. This study assessed these outcomes and developed a new allocation system that balances equity and utility.
Patients from national and hospital cohorts from two centers in Korea were categorized as B1 to B4 (according to panel reactive antibody [PRA] positivity and ABO blood type) and A1 to A4 (based on the maximal PRA% and blood type), respectively. Competing risk and Cox regression analyses were performed to assess the effects of PRA and blood type on graft failure and mortality, respectively. Based on DDKT opportunities and posttransplant outcomes, a new scoring system for kidney allocation was developed.
The national and hospital cohorts included 3,311 and 819 patients, respectively, who underwent DDKT. Despite the disparities in DDKT opportunities, the graft failure rates and mortality did not differ among the different PRA and blood type groups. Furthermore, posttransplantation outcomes did not differ according to the categories with different DDKT opportunities. A new scoring system to provide additional points to disadvantaged populations was developed based on the hazard ratios for DDKT.
A new allocation approach based on PRA and ABO blood types offers benefits to disadvantaged patients with fewer DDKT opportunities and could enhance equity without sacrificing utility in Korea, which has a long waiting time for DDKT.
致敏且血型为O型的患者在接受 deceased-donor 肾移植(DDKT)时等待时间会增加。虽然需要分配福利来解决 DDKT 机会的不平等问题,但在这一弱势群体中 DDKT 是否具有可比的结果仍需进一步研究。本研究评估了这些结果,并开发了一种平衡公平性和实用性的新分配系统。
来自韩国两个中心的国家队列和医院队列的患者分别被分类为B1至B4(根据群体反应性抗体[PRA]阳性和ABO血型)和A1至A4(基于最大PRA%和血型)。分别进行竞争风险分析和Cox回归分析,以评估PRA和血型对移植肾失功和死亡率的影响。基于DDKT机会和移植后结果,开发了一种新的肾脏分配评分系统。
国家队列和医院队列分别包括3311例和819例接受DDKT的患者。尽管DDKT机会存在差异,但不同PRA和血型组之间的移植肾失功率和死亡率并无差异。此外,根据不同DDKT机会的类别,移植后结果也没有差异。基于DDKT的风险比,开发了一种为弱势群体提供额外分数的新评分系统。
基于PRA和ABO血型的新分配方法为DDKT机会较少的弱势患者带来了益处,并且在韩国这种DDKT等待时间较长的情况下,在不牺牲实用性的前提下可以提高公平性。